ConcePTION

Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation
ConcePTION logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 13
Grant agreement number
821520

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
15 299 991
EFPIA in kind
13 387 500
Other
90 916
Total Cost
28 778 407

Summary

Women who are pregnant or breastfeeding are traditionally excluded from medical research due to safety concerns. As a result of this, only 5 % of medications have adequate safety information on their use in pregnant or breastfeeding women, and this makes it very hard for doctors and women to make informed decisions about their treatment. Nonetheless, some 90 % of women are exposed to a prescription medication at some point during their pregnancy. The ultimate goal of ConcePTION is to create a trusted biomedical ecosystem capable of providing evidence-based information on the safety of medications during pregnancy and breastfeeding in an efficient, systematic and ethically responsible way. The information will be provided in a form that is usable by both healthcare providers and patients alike. The project will achieve this in a number of ways. Firstly, it will improve and unify existing approaches to data collection in this area by re-using existing, de-identified data generated during routine patient care. The project also aims to deliver procedures and tools for the collection of digital data and samples directly from pregnant women. They will also create the first Europe-wide breast milk biobank for research purposes, and develop tools to predict which drugs are likely to be transferred to breast milk. Finally, the team will establish a web-based drug information knowledge bank.

Achievements & News

IMI’s EHDEN and ConcePTION projects to work with EMA on COVID-19
July 2020

The EHDEN and ConcePTION projects plus the ADVANCE/VAC4EU initiative will help the European Medicines Agency (EMA) gather real world data on COVID-19 vaccines and treatments once they are approved and being used in day-to-day clinical practice.###

EHDEN is already working with 25 data partners across Europe, to help them map COVID-19 data to a common data model. Now, it is set to collaborate with the EMA on the creation of a framework for multicentre cohort studies on the use of medicines in COVID-19 patients.

ConcePTION will collaborate with the EMA on a project that will collect data on the impact of COVID-19 in pregnancy and follow up the baby to monitor long-term outcomes in order to guide decision-making about vaccine indications, vaccination policies and treatment options for COVID-19 in pregnant women.

The international association VAC4EU (Vaccine Monitoring Collaboration for Europe) is set to work with the EMA to prepare for the monitoring of the benefits and risks of COVID-19 vaccines in Europe. VAC4EU was born out of IMI’s ADVANCE project.

‘The inclusion of EHDEN, ConcePTION and VAC4EU in the EMA’s work is testament not only to their scientific excellence but to their ability to adapt to the challenges posed by the COVID-19 pandemic,’ said IMI Executive Director Pierre Meulien. ‘I am confident that the projects will make a valuable contribution to this important initiative which is a key part of the global fight against the disease.’

The outcomes of the projects will feed into the work of EMA’s COVID-19 EMA pandemic Task Force (COVID-ETF) and EMA’s scientific committees, to ensure that the evidence is translated into scientific opinions on the optimal use of the medicines and vaccines concerned.

Find out more

Contribute to the survey on medication safety for new and expectant mothers
October 2019

Evidence suggests that up to 95 % of the five million women who get pregnant in the EU every year will reach for a prescription drug at some point. And yet, only about 5 % of the medication they take comes with pregnancy and breast-feeding-related safety information. Now, IMI’s ConcePTION project is working to fill the data gap. ###As a first step, they are running a survey to gather as much information as possible about how women who are pregnant or breastfeeding are currently making choices about medication.

Elsewhere, the project aims to establish new and better ways to collect digital data and samples; create a Europe-wide breast milk biobank for research; develop tools to predict transferability of drugs medicines into breastmilk; and build a web-based drug info bank, presented in a way that women have a reliable single source and don’t need a medical degree to understand.

Participants Show participants on map

EFPIA companies
  • Abbvie Inc, North Chicago, Illinois, United States
  • Bristol-Myers Squibb Company Corp, Princeton, NJ, United States
  • Covance Laboratories LTD, Harrogate, United Kingdom
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • Ellegaard Gottingen Minipigs As, Dalmose, Denmark
  • Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany
  • Novartis Pharma AG, Basel, Switzerland
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
  • Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland
  • Teva Pharmaceutical Industries Limited, Netanya, Israel
  • UCB Biopharma SRL, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • Agenzia Regionale Di Sanita, Firenze, Italy
  • Alma Mater Studiorum - Universita Di Bologna, Bologna, Italy
  • Biobanks And Biomolecular Resources Research Infrastructure Consortium (Bbmri-Eric), Graz, Austria
  • Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 09, France
  • Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
  • Consiglio Nazionale Delle Ricerche, Roma, Italy
  • European Forum For Good Clinical Practice, Brussels, Belgium
  • European Institute Of Women'S Health Company Limited By Guarantee, Dublin, Ireland
  • Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana, Valencia, Spain
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
  • Karolinska Institutet, Stockholm, Sweden
  • Katholieke Universiteit Leuven, Leuven, Belgium
  • Medicines And Healthcare Products Regulatory Agency, London, United Kingdom
  • Region Stockholm, Stockholm, Sweden
  • Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands
  • St George'S Hospital Medical School, London, United Kingdom
  • Stichting Entis (European Network Teratology Information Services) Foundation, Hertogenbosch, Netherlands
  • Stichting Lareb, 's Hertogenbosch, Netherlands
  • Swansea University, Swansea, United Kingdom
  • Terveyden Ja Hyvinvoinnin Laitos, Helsinki, Finland
  • The European Institute For Innovation Through Health Data, Gent, Belgium
  • The European Medicines Agency, Canary Wharf, London, United Kingdom
  • The Newcastle Upon Tyne Hospitals Nhs Foundation Trust, Newcastle-Upon-Tyne, United Kingdom
  • The University Of Manchester, Manchester, United Kingdom
  • Universita Degli Studi Di Ferrara, Ferrara, Italy
  • Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
  • Universitetet I Oslo, Oslo, Norway
  • University Of Kwazulu-Natal, Westville, South Africa
  • University Of Ulster, Coleraine, United Kingdom
  • Uppsala Universitet, Uppsala, Sweden
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Bionotus, Temse, Belgium
  • Elevate BV, Utrecht, Netherlands
  • Orcion BV, Asten, Netherlands
  • The Synergist, Bruxelles, Belgium
  • Ttopstart BV, Bilthoven, Netherlands
Third parties
  • Izmir Katip Celebi Universitesi, Izmir, Turkey
  • Masarykova univerzita, Brno, Czech Republic
  • Medizinische Universitat Graz, Graz, Austria
  • Ministry Of Health, Jerusalem, Israel
  • Region Syddanmark, Odense, Denmark
  • Synergist Services, Bruxelles, Belgium
  • Universitaet Leipzig, Leipzig, Germany
  • Uniwersytet Medyczny Im Piastow Slaskich We Wroclawiu, Wroclaw, Poland
Project coordinator
Miriam Sturkenboom
Universitair Medisch Centrum Utrecht